Sweden · Delayed Price · Currency is SEK EQL Pharma AB Statistics
Total Valuation
EQL Pharma AB has a market cap or net worth of SEK 776.63 million. The enterprise value is 1.18 billion.
| Market Cap | 776.63M |
| Enterprise Value | 1.18B |
Important Dates
The last earnings date was Friday, August 7, 2026.
| Earnings Date | Aug 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
EQL Pharma AB has 29.53 million shares outstanding. The number of shares has decreased by -1.52% in one year.
| Current Share Class | 29.53M |
| Shares Outstanding | 29.53M |
| Shares Change (YoY) | -1.52% |
| Shares Change (QoQ) | -2.12% |
| Owned by Insiders (%) | 3.77% |
| Owned by Institutions (%) | 9.48% |
| Float | 12.80M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 21.43 |
| PS Ratio | 1.80 |
| PB Ratio | 3.10 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 36.61 |
| P/OCF Ratio | 36.51 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 32.89, with an EV/FCF ratio of 55.40.
| EV / Earnings | n/a |
| EV / Sales | 2.72 |
| EV / EBITDA | 32.89 |
| EV / EBIT | 85.78 |
| EV / FCF | 55.40 |
Financial Position
The company has a current ratio of 1.83, with a Debt / Equity ratio of 1.84.
| Current Ratio | 1.83 |
| Quick Ratio | 0.83 |
| Debt / Equity | 1.84 |
| Debt / EBITDA | 12.86 |
| Debt / FCF | 21.67 |
| Interest Coverage | 0.53 |
Financial Efficiency
Return on equity (ROE) is -5.84% and return on invested capital (ROIC) is 2.13%.
| Return on Equity (ROE) | -5.84% |
| Return on Assets (ROA) | 1.06% |
| Return on Invested Capital (ROIC) | 2.13% |
| Return on Capital Employed (ROCE) | 2.21% |
| Weighted Average Cost of Capital (WACC) | 5.12% |
| Revenue Per Employee | 6.65M |
| Profits Per Employee | -216,046 |
| Employee Count | 23 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 1.59 |
Taxes
| Income Tax | -1.24M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -69.24% in the last 52 weeks. The beta is 0.23, so EQL Pharma AB's price volatility has been lower than the market average.
| Beta (5Y) | 0.23 |
| 52-Week Price Change | -69.24% |
| 50-Day Moving Average | 22.84 |
| 200-Day Moving Average | 44.31 |
| Relative Strength Index (RSI) | 67.17 |
| Average Volume (20 Days) | 66,082 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, EQL Pharma AB had revenue of SEK 432.35 million and -14.04 million in losses. Loss per share was -0.47.
| Revenue | 432.35M |
| Gross Profit | 134.53M |
| Operating Income | 13.70M |
| Pretax Income | -15.28M |
| Net Income | -14.04M |
| EBITDA | 34.31M |
| EBIT | 13.70M |
| Loss Per Share | -0.47 |
Balance Sheet
The company has 61.10 million in cash and 459.69 million in debt, with a net cash position of -398.60 million or -13.50 per share.
| Cash & Cash Equivalents | 61.10M |
| Total Debt | 459.69M |
| Net Cash | -398.60M |
| Net Cash Per Share | -13.50 |
| Equity (Book Value) | 250.31M |
| Book Value Per Share | 8.48 |
| Working Capital | 164.74M |
Cash Flow
In the last 12 months, operating cash flow was 21.27 million and capital expenditures -57,000, giving a free cash flow of 21.22 million.
| Operating Cash Flow | 21.27M |
| Capital Expenditures | -57,000 |
| Depreciation & Amortization | 20.61M |
| Net Borrowing | 4.04M |
| Free Cash Flow | 21.22M |
| FCF Per Share | 0.72 |
Margins
Gross margin is 31.11%, with operating and profit margins of 3.17% and -3.25%.
| Gross Margin | 31.11% |
| Operating Margin | 3.17% |
| Pretax Margin | -3.53% |
| Profit Margin | -3.25% |
| EBITDA Margin | 7.94% |
| EBIT Margin | 3.17% |
| FCF Margin | 4.91% |
Dividends & Yields
EQL Pharma AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.52% |
| Shareholder Yield | 1.52% |
| Earnings Yield | -1.81% |
| FCF Yield | 2.73% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |